PD-L1

[Clinical Cancer Research] Digital image analysis of whole section slides was used to assess abundance and spatial distribution of T cells and tertiary lymphoid structures in the tumor immune microenvironment of 117 tumor samples.

[Nature Reviews Clinical Oncology] The authors describe the roles of the diverse post-translational modifications of PD-L1, including phosphorylation, palmitoylation, glycosylation, acetylation and ubiquitination.

[Science Advances] Researchers found that TSC1/TSC2 loss defined a distinct subtype of NSCLC characterized as inflamed tumor microenvironment and superior sensitivity to immune checkpoint blockade.

[Cell Reports] To determine the role of programmed death-ligand 1 (PD-L1) in myofibroblastic activation of hepatic stellate cells (HSCs), researchers disrupted PD-L1 of HSCs by shRNA or anti-PD-L1 antibody.

[NeoImmuneTech, Inc. (Businesswire, Inc.)] NeoImmuneTech, Inc. announced that the first patient has been dosed in the Phase IIa portion of a study evaluating NT-I7, a novel long-acting human interleukin-7, in combination with the PD-L1 targeting drug atezolizumab, in patients with advanced high-risk skin cancers including melanoma, merkel cell carcinoma, and cutaneous squamous cell carcinoma.

[Cell Death & Disease] Niclosamide inhibited proliferation of pancreatic cancer cells, induced apoptosis via the mitochondrial-mediated pathway, and suppressed cell migration and invasion by antagonizing epithelial-to-mesenchymal transition.